Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

eli lilly (suisse) sa - baricitinibum - filmtabletten - comprimé pelliculé: baricitinibum 2 mg, mannitolum 52 mg, cellulosum microcristallinum, carmellosum natricum conexum, magnesii stearas, pellicule: poly(alcohol vinylicus), macrogolum, talcum, lecithinum ex soja, e 171, e 172 (rubrum), pro compresso obducto, natrium 0.7608 mg. - polyarthrite rhumatoïde / dermatite atopique / covid 19 / alopecia areata - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

eli lilly (suisse) sa - baricitinibum - filmtabletten - comprimé pelliculé: baricitinibum 4 mg, mannitolum 50 mg, cellulosum microcristallinum, carmellosum natricum conexum, magnesii stearas, pellicule: poly(alcohol vinylicus), macrogolum, talcum, lecithinum ex soja, color.: e 171, e 172 (rubrum), pro compresso obducto, natrium 0.7608 mg. - polyarthrite rhumatoïde / dermatite atopique / covid 19 / alopecia areata - synthetika

Europäische Union - Deutsch - EMA (European Medicines Agency)

eli lilly nederland b.v. - baricitinib - arthritis, rheumatoide - immunsuppressiva - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). olumiant kann als monotherapie oder in kombination mit methotrexat verwendet werden. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.